Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension

Circulation

Volumn 107, Issue 25, 2003, Pages 3230-3235

  Sebkhi, A ^a   Strange, Julian W ^a   Phillips, Steven C ^b   Wharton, John ^a   Wilkins, Martin R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Hypertension, pulmonary; Hypoxia; Inhibitors; Telemetry

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; ENZYME INHIBITION; ENZYME LOCALIZATION; HYPOXIA; LUNG ARTERY PRESSURE; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER; TELEMETRY; TREATMENT OUTCOME; WESTERN BLOTTING;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; ANOXIA; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; LUNG; MALE; MUSCLE, SMOOTH, VASCULAR; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; PULMONARY ARTERY; PULMONARY CIRCULATION; PULMONARY VEINS; RATS; RATS, SPRAGUE-DAWLEY; TELEMETRY; VASODILATOR AGENTS;

EID: 0037741441     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000074226.20466.B1     Document Type: Article

References (23)

1. Hislop A, Reid L. New findings in pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. Br J Path. 1976;57:542-554.
2. Heath D, Williams D, Rios-Dalenz J, et al. Small pulmonary arterial vessels of Aymara Indians from the Bolivian Andes. Histopathology. 1990;16:565-571.
3. Wilkinson M, Langhorne CA, Heath D, et al. A pathophysiological study of 10 cases of hypoxic cor pulmonale. Q J Med. 1988;249:65-85.
4. Zhao L, al Tubuly R, Sebkhi A, et al. Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung. Br J Pharmacol. 1996;119:1217-1222.
5. Zhao L, Winter RJD, Krauz T, et al. Effects of continuous infusion of atrial natriuretic peptide on the pulmonary hypertension induced by chronic hypoxia in rats. Clin Sci. 1991;81:379-385.
6. Thomas MK, Francis SH, Corbin JD. Characterisation of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem. 1990;265:14964-14970.
7. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation. 2001;104:424-428.
8. Hess P, Clozel M, Clozel J-P. Telemetry monitoring of pulmonary arterial pressure in freely moving rats. J Applied Physiol. 1996;81:1027-1032.
9. Winter RJD, Keast CG, Butler PRE, et al. Use of a flexible film isolator as a single circuit hypoxic chamber for small animals. Lab Animals. 1985;19:258-261.
10. Walker DK, Ackland MJ, James GC, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 1999;29:297-310.
11. Stacey P, Rulten S, Dapling A, et al. Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Biophys Res Commun. 1999;247:249-254.
12. Fawcett L, Baxendale R, Stacey P, et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci U S A. 2000;97:3702-3707.
13. Cattoretti G, Pileri S, Parravicini C, et al. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol. 1993;171:83-98.
14. MacLean MR, Johnston ED, McCulloch KM, et al. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther. 1997;283:619-624.
15. Hanson KA, Ziegler JW, Rybalkin SD, et al. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol. 1998;275:L931-L941.
16. Black SM, Sanchez LS, Mata-Greenwood E, et al. sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2001;281:L1051-L1057.
17. Rybalkin SD, Rybalkina IG, Feil R, et al. Regulafion of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem. 2002;277:3310-3317.
18. Muramatsu M, Tyler RC, Gutkowska J, et al. Atrial natriuretic peptide accounts for increased cGMP in hypoxia-induced hypertensive rat lungs. Am J Physiol. 1997;272:L1126-L1132.
19. Hanasato N, Oka M, Muramatsu M, et al. E4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol. 1999;277:L225-L232.
20. Fried R, Reid LM. Early recovery from hypoxic pulmonary hypertension: a structural and functional study. J Appl Physiol. 1984;57:1247-1253.
21. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-301.
22. Jackson G, Benjamin N, Jackson N, et al. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol. 1999;83:13C-20C.
23. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105:2398-2403.